Cullen Frost Bankers Inc. Grows Position in Royalty Pharma PLC $RPRX

Posted by George Bondi on May 20th, 2026

Cullen Frost Bankers Inc. raised its position in Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 19.5% during the fourth quarter, HoldingsChannel.com reports. The firm owned 546,350 shares of the biopharmaceutical company’s stock after buying an additional 89,253 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in Royalty Pharma were worth $21,111,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Strs Ohio raised its holdings in shares of Royalty Pharma by 2.8% in the 4th quarter. Strs Ohio now owns 9,318 shares of the biopharmaceutical company’s stock worth $360,000 after purchasing an additional 252 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of Royalty Pharma by 0.6% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 43,287 shares of the biopharmaceutical company’s stock worth $1,673,000 after purchasing an additional 255 shares during the period. Private Trust Co. NA grew its stake in shares of Royalty Pharma by 52.9% in the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 288 shares in the last quarter. Hudson Bay Capital Management LP grew its stake in shares of Royalty Pharma by 1.0% in the third quarter. Hudson Bay Capital Management LP now owns 29,384 shares of the biopharmaceutical company’s stock valued at $1,037,000 after buying an additional 289 shares in the last quarter. Finally, Truist Financial Corp grew its stake in shares of Royalty Pharma by 1.1% in the fourth quarter. Truist Financial Corp now owns 27,769 shares of the biopharmaceutical company’s stock valued at $1,073,000 after buying an additional 303 shares in the last quarter. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on RPRX. Wall Street Zen upgraded Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. The Goldman Sachs Group reiterated a “buy” rating on shares of Royalty Pharma in a research note on Thursday, February 12th. JPMorgan Chase & Co. increased their target price on Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. TD Cowen reiterated a “buy” rating on shares of Royalty Pharma in a research note on Friday, February 27th. Finally, Citigroup raised their price objective on Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Seven equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $53.71.

View Our Latest Stock Analysis on Royalty Pharma

Royalty Pharma Price Performance

Shares of NASDAQ RPRX opened at $52.41 on Wednesday. Royalty Pharma PLC has a fifty-two week low of $32.15 and a fifty-two week high of $53.47. The business has a 50 day moving average price of $48.58 and a two-hundred day moving average price of $43.61. The company has a quick ratio of 2.66, a current ratio of 2.66 and a debt-to-equity ratio of 0.86. The firm has a market cap of $30.18 billion, a PE ratio of 35.65, a price-to-earnings-growth ratio of 1.43 and a beta of 0.40.

Royalty Pharma (NASDAQ:RPRX – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%.The firm had revenue of $631.00 million during the quarter, compared to analyst estimates of $881.69 million. Sell-side analysts expect that Royalty Pharma PLC will post 5.05 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be given a $0.235 dividend. The ex-dividend date is Friday, May 15th. This represents a $0.94 annualized dividend and a dividend yield of 1.8%. Royalty Pharma’s dividend payout ratio (DPR) is presently 63.95%.

Insider Transactions at Royalty Pharma

In other news, EVP Marshall Urist sold 13,684 shares of Royalty Pharma stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $53.06, for a total value of $726,073.04. Following the completion of the transaction, the executive vice president owned 31,881 shares in the company, valued at approximately $1,691,605.86. This trade represents a 30.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gregory Norden sold 3,045 shares of Royalty Pharma stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $53.00, for a total value of $161,385.00. Following the completion of the transaction, the director owned 191,803 shares of the company’s stock, valued at approximately $10,165,559. The trade was a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 155,893 shares of company stock worth $7,512,360. 18.84% of the stock is currently owned by corporate insiders.

Royalty Pharma Company Profile

(Free Report)

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.